Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation September 17, 2025 September 17, 2025
Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to the Board of Directors September 12, 2025 September 12, 2025
Medincell to Present at the H.C. Wainwright 27th Global Investment Conference and Participate in the Morgan Stanley 23rd Global Healthcare Conference September 5, 2025 September 5, 2025
UZEDY® Accelerates: 2025 Revenue Outlook Raised to $190–$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025 July 30, 2025 July 30, 2025
Medincell Proposes Board Appointments of Dr. Sharon Mates and Dr. Charles Kunsch July 29, 2025 July 29, 2025
Truist Securities Initiates Medincell’s Coverage with a “Buy” Recommendation May 28, 2025 May 28, 2025
UZEDY® Continues Strong Momentum in 2025; Olanzapine LAI on Track for FDA Filing in H2 2025 May 7, 2025 May 7, 2025
